Skip to main content

Table 3 Patient characteristics in subgroups according to age >/≤ 65 years

From: Clinical characteristics and blood/serum bound prognostic biomarkers in advanced pancreatic cancer treated with gemcitabine and nab-paclitaxel

  ≤65
(n = 36)
> 65
(n = 39)
p-value
Female 18 (50) 16 (41) 0.435
Prior Surgery 10 (28) 17 (44) 0.154
Localised disease/M0 7 (19) 15 (38) 0.070
CA19–9(median)a 980 476 0.057
ECOG 0 17 (47) 16 (41) 0.589
ECOG 1 17 (47) 19 (49) 0.897
ECOG 2 2 (6) 4 (10) 0.453
Adjuvant chemotherapy 8 (22) 16 (41) 0.081
Neoadjuvant chemotherapy 2 (6) 1 (3) 0.509
S-albumin (mean) 37.7 36.6 0.335
S-albumin (median) 39 37 0.203
N cycles (median) 3 5 0.061
Thrombocytopenia 21 (58) 27 (69 0.326
BM-toxicity G3–4 9 (25) 14 (36) 0.307
Dose intensity Gem (mean) 79% 73% 0.214
Dose intensity NabP (mean) 75% 63% 0.028
Full dose 25% 10% 0.092
2nd line treatmentb 45% 55% 0.438
  1. Number (%) where not otherwise stated. aDropouts were 5 and 3 in the young and elderly group, respectively. bDropouts were 5 and 10 in the young and elderly group, respectively. Statistical significance at the 0.05 level marked in bold text.
\